Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nebius Group NV (NBIS) vs Tilray Brands Inc (TLRY) Price & Performance

Nebius Group NVTrade
Tilray Brands IncTrade

Price performance (Past 24H)

Key statistics

Nebius Group NV vs Tilray Brands Inc — how do they compare? Nebius Group NV trades at $236.3 (market cap $66.30B), while Tilray Brands Inc trades at $4.21 (market cap $591.60M). The key difference: Nebius Group NV is far larger — about 112.1× Tilray Brands Inc's market cap, and Nebius Group NV is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.

NBISTLRY
Market Cap
$66.30B$591.60M
Sector
TechnologyHealth
52-Week High
$286.69$21.00
52-Week Low
$73.87$3.88
Enterprise Value
$68.43B$758.73M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nebius Group NV

NBIS stock surged 7.73% to $243.88 following a strategic partnership announcement with Palantir as its preferred sovereign AI infrastructure partner. The stock trades near its pivot point of $244 with bullish technical indicators and strong analyst support (80% buy ratings). Despite high valuation multiples (P/E 74.61, P/S 49.83), the company shows improving earnings trends with recent quarterly beats and projected revenue growth from $530M to $1.4B in 2026.

The outlook remains positive with a consensus price target of $291.33 (19% upside), driven by AI infrastructure demand and the Palantir partnership. Key risks include stretched valuations, negative operating cash flow relative to investments, and execution challenges in scaling capacity. The stock presents growth potential but requires careful monitoring of profitability improvements and contract execution.

Tilray Brands Inc

TLRY trades at $4.30, down 4.44% today, reflecting ongoing investor skepticism despite record fiscal 2026 revenue of $915 million. The stock shows bearish technical signals with key support at $4.00, while fundamentals reveal significant challenges including negative net income margins (-13.26%) and consecutive earnings misses. Recent developments include strategic partnerships expansion in New York and California spirits markets and increased medical cannabis production capacity to 275 metric tonnes.

TLRY faces substantial execution risks with persistent losses and negative cash flow, though trading below book value (P/B 0.37) offers potential value. Analyst consensus remains cautious with 65% hold ratings, while regulatory progress in cannabis remains a key catalyst. The stock requires successful margin improvement and U.S. regulatory clarity for sustained recovery.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Nebius Group NV

Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.

Read more on NBIS

About Tilray Brands Inc

Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.

Read more on TLRY